ATE403657T1 - Chemische verbindungen - Google Patents

Chemische verbindungen

Info

Publication number
ATE403657T1
ATE403657T1 AT02776075T AT02776075T ATE403657T1 AT E403657 T1 ATE403657 T1 AT E403657T1 AT 02776075 T AT02776075 T AT 02776075T AT 02776075 T AT02776075 T AT 02776075T AT E403657 T1 ATE403657 T1 AT E403657T1
Authority
AT
Austria
Prior art keywords
chemical compounds
derivatives
methods
pyrazolo
diseases
Prior art date
Application number
AT02776075T
Other languages
English (en)
Inventor
Jerry Adams
Jiri Kasparec
Domingos Silva
Catherine Yuan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE403657T1 publication Critical patent/ATE403657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT02776075T 2001-10-02 2002-10-01 Chemische verbindungen ATE403657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32650601P 2001-10-02 2001-10-02

Publications (1)

Publication Number Publication Date
ATE403657T1 true ATE403657T1 (de) 2008-08-15

Family

ID=23272496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02776075T ATE403657T1 (de) 2001-10-02 2002-10-01 Chemische verbindungen

Country Status (8)

Country Link
US (1) US7217710B2 (de)
EP (1) EP1432714B1 (de)
JP (1) JP4459619B2 (de)
AT (1) ATE403657T1 (de)
AU (1) AU2002341920A1 (de)
DE (1) DE60228103D1 (de)
ES (1) ES2309206T3 (de)
WO (1) WO2003029209A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106340A2 (en) * 2003-05-28 2004-12-09 Università Degli Studi Di Siena 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
JP2007517007A (ja) * 2003-12-24 2007-06-28 アストラゼネカ アクチボラグ Ｔｉｅ２（ＴＥＫ）活性を持つピリミジン
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
KR100843526B1 (ko) * 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
EP1747202A1 (de) 2004-02-27 2007-01-31 F.Hoffmann-La Roche Ag Indazolderivate und pharmazeutische zusammensetzungen, die diese enthalten
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
CA2578384A1 (en) 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
JP2008528662A (ja) * 2005-02-01 2008-07-31 アストラゼネカ アクチボラグ Ｔｉｅ２（ＴＥＫ）阻害活性を有するピリミジン化合物
JP2008528663A (ja) * 2005-02-01 2008-07-31 アストラゼネカ アクチボラグ Ｔｉｅｓ（ＴＥＫ）阻害活性を有するピリミジン化合物
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
CN101243088B (zh) 2005-08-25 2011-06-29 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
EP1949894B1 (de) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Verstärkung von vanadiumhaltigen Phosphatasehemmern mit Polyole
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
EP2252616B1 (de) * 2008-01-30 2014-07-23 Genentech, Inc. Pyrazolopyrimidin als pi3k-inhibitorverbindungen und anwendungsverfahren
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
CA2744154A1 (en) 2008-11-20 2010-05-27 Genentech, Inc. Pyrazolopyridine pi3k inhibitor compounds and methods of use
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5677425B2 (ja) 2009-06-29 2015-02-25 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのピリミジノン
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2643320B1 (de) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors
EP2649069B1 (de) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
EP2655374B1 (de) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituierte phenyl)ethyl)-9h-purin-6-amine als pi3k-hemmer
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
IN2014DN01883A (de) * 2011-09-14 2015-05-15 Proximagen Ltd
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
CA2850617A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013177168A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (de) 2012-11-27 2016-06-01 Univ North Carolina Pyrimidinverbindungen zur krebsbehandlung
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
WO2015157125A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN105272930B (zh) 2014-07-17 2018-07-13 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
WO2019236631A1 (en) * 2018-06-05 2019-12-12 Rapt Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
KR20210102285A (ko) 2018-12-06 2021-08-19 알막 디스커버리 리미티드 약학적 화합물 및 유비퀴틴 특이적 단백질분해효소 19 (usp19)의 억제제로서의 사용

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304859A (en) * 1995-04-03 2000-01-28 Novartis Ag 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AU4779897A (en) * 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
SK3812002A3 (en) * 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents

Also Published As

Publication number Publication date
US7217710B2 (en) 2007-05-15
ES2309206T3 (es) 2008-12-16
EP1432714A2 (de) 2004-06-30
DE60228103D1 (de) 2008-09-18
EP1432714B1 (de) 2008-08-06
JP2005504828A (ja) 2005-02-17
US20040198751A1 (en) 2004-10-07
JP4459619B2 (ja) 2010-04-28
AU2002341920A1 (en) 2003-04-14
WO2003029209A3 (en) 2004-02-12
EP1432714A4 (de) 2005-10-19
WO2003029209A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
DE60228103D1 (de) Chemische verbindungen
NO2022001I1 (no) Pazopanib
WO2003106416A3 (en) CHEMICAL PROCESS
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE60314623D1 (de) Substituierte pyrazolopyrimidine
EA200700225A1 (ru) Аналоги тетрапептида
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
WO2003051886A8 (en) Pyrazolopyridazine derivatives
WO2003072541A3 (en) Chemical compounds
WO2004043379A3 (en) Chemical compounds
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE404550T1 (de) Chemische verbindungen
NO20053562L (no) Nye aminobenzofenonforbindelser
DE60106947D1 (de) Oxindolderivate
DE60123103D1 (de) Neue verbindungen
ATE294167T1 (de) Chemische verbindungen
ATE344666T1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties